Post by
fossi_2002 on Nov 10, 2022 10:56am
Future
Q3 results are out and the stock market has reacted. That's it for now.
Now the stock market will look to the future again, and we can be confidently optimistic about this.
Never in Ceapro's past has the future been so broad. All projects have great future opportunities - and all projects are paid for by the core business.
Compare Ceapro with other small companies and you will see how much money they burn quarter after quarter and constantly have to issue new shares to finance their research activities.
The course is not being set now, it is already pointing in the right direction.
By the end of 2023, Ceapro will be a company with a completely different face and with a completely different stock market valuation.
Those on the bullboard who are still whining bought at the wrong time. Now they are whining because they missed the time to get in again. They will probably never make money on the stock market.
Comment by
Ciao on Nov 10, 2022 11:10am
Agreed. Fundamentally the company is now in the best position it has ever been. Bioavailability with low cost PGX substrates which can carry bioactives (which on their own are not water soluable ) to desired tissues is the proof of concept that Ceapro needed to move forward to commerical applications of PGX. Cash on hand is able to fund the scale up of a mid sized commercial plant.